PMID- 32527257
OWN - NLM
STAT- MEDLINE
DCOM- 20200625
LR  - 20201218
IS  - 1475-2840 (Electronic)
IS  - 1475-2840 (Linking)
VI  - 19
IP  - 1
DP  - 2020 Jun 11
TI  - Impact of diabetes mellitus on clinical outcomes in patients affected by 
      Covid-19.
PG  - 76
LID - 10.1186/s12933-020-01047-y [doi]
LID - 76
AB  - A possible association could exist between type 2 diabetes mellitus (T2DM) and 
      Coronavirus-19 (Covid-19) infection. Indeed, patients with T2DM show high 
      prevalence, severity of disease and mortality during Covid-19 infection. However, 
      the rates of severe disease are significantly higher in patients with diabetes 
      compared with non-diabetes (34.6% vs. 14.2%; p < 0.001). Similarly, T2DM patients 
      have higher rates of need for Intensive Care Unit (ICU, 37.0% vs. 26.7%; 
      p = 0.028). Thus, about the pneumonia of Covid-19, we might speculate that the 
      complicated alveolar-capillary network of lungs could be targeted by T2DM 
      micro-vascular damage. Therefore, T2DM patients frequently report respiratory 
      symptoms and are at increased risk of several pulmonary diseases. In addition, 
      pro-inflammatory pathways as that involving interleukin 6 (IL-6), could be a 
      severity predictor of lung diseases. Therefore, it looks intuitive to speculate 
      that this condition could explain the growing trend of cases, hospitalization and 
      mortality for patients with T2DM during Covid-19 infection. To date, an ongoing 
      experimental therapy with monoclonal antibody against the IL-6 receptor in Italy 
      seems to have beneficial effects on severe lung disease and prognosis in patients 
      with Covid-19 infection. Therefore, should patients with T2DM be treated with 
      more attention to glycemic control and monoclonal antibody against the IL-6 
      receptor during the Covid-19 infection?
FAU - Sardu, Celestino
AU  - Sardu C
AUID- ORCID: 0000-0001-5099-3790
AD  - Department of Advanced Medical and Surgical Sciences (DAMSS), University of 
      Campania "Luigi Vanvitelli", Piazza Miraglia, 2, 80138, Naples, Italy. 
      drsarducele@gmail.com.
FAU - Gargiulo, Giuseppe
AU  - Gargiulo G
AD  - Division of Cardiology, Department of Advanced Biomedical Sciences, University 
      Federico II of Naples, Via S. Pansini 5, 80131, Naples, Italy.
FAU - Esposito, Giovanni
AU  - Esposito G
AD  - Division of Cardiology, Department of Advanced Biomedical Sciences, University 
      Federico II of Naples, Via S. Pansini 5, 80131, Naples, Italy.
FAU - Paolisso, Giuseppe
AU  - Paolisso G
AD  - Department of Advanced Medical and Surgical Sciences (DAMSS), University of 
      Campania "Luigi Vanvitelli", Piazza Miraglia, 2, 80138, Naples, Italy.
FAU - Marfella, Raffaele
AU  - Marfella R
AD  - Department of Advanced Medical and Surgical Sciences (DAMSS), University of 
      Campania "Luigi Vanvitelli", Piazza Miraglia, 2, 80138, Naples, Italy.
LA  - eng
PT  - Editorial
DEP - 20200611
PL  - England
TA  - Cardiovasc Diabetol
JT  - Cardiovascular diabetology
JID - 101147637
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Blood Glucose)
RN  - 0 (IL6R protein, human)
RN  - 0 (Receptors, Interleukin-6)
SB  - IM
MH  - Antibodies, Monoclonal, Humanized/pharmacology/*therapeutic use
MH  - Betacoronavirus/*metabolism
MH  - Blood Glucose/drug effects/*metabolism
MH  - COVID-19
MH  - Coronavirus Infections/*blood/drug therapy/epidemiology
MH  - Diabetes Mellitus, Type 2/*blood/drug therapy/epidemiology
MH  - Glycemic Index/drug effects/physiology
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/*blood/drug therapy/epidemiology
MH  - Receptors, Interleukin-6/antagonists & inhibitors/blood
MH  - SARS-CoV-2
MH  - Treatment Outcome
PMC - PMC7289072
OTO - NOTNLM
OT  - Covid-19
OT  - Micro-vascular disease
OT  - Several disease
OT  - Type 2 diabetes mellitus
COIS- The authors declare that they have no competing interests in this section.
EDAT- 2020/06/13 06:00
MHDA- 2020/06/26 06:00
PMCR- 2020/06/11
CRDT- 2020/06/13 06:00
PHST- 2020/04/13 00:00 [received]
PHST- 2020/05/30 00:00 [accepted]
PHST- 2020/06/13 06:00 [entrez]
PHST- 2020/06/13 06:00 [pubmed]
PHST- 2020/06/26 06:00 [medline]
PHST- 2020/06/11 00:00 [pmc-release]
AID - 10.1186/s12933-020-01047-y [pii]
AID - 1047 [pii]
AID - 10.1186/s12933-020-01047-y [doi]
PST - epublish
SO  - Cardiovasc Diabetol. 2020 Jun 11;19(1):76. doi: 10.1186/s12933-020-01047-y.